Peter, S.; Morifi, E.; Nwamadi, M.; Oselusi, S.O.; Tantoh, A.L.; Fonkui, T.Y.; Ndinteh, D.T.; Aderibigbe, B.A.
Ferrocene-Based Hybrid Drugs as Potential Anticancer and Antibacterial Therapeutic Agents for Incorporation into Nanocarriers: In Silico, In Vitro, Molecular Docking Evaluations. Pharmaceutics 2025, 17, 722.
https://doi.org/10.3390/pharmaceutics17060722
AMA Style
Peter S, Morifi E, Nwamadi M, Oselusi SO, Tantoh AL, Fonkui TY, Ndinteh DT, Aderibigbe BA.
Ferrocene-Based Hybrid Drugs as Potential Anticancer and Antibacterial Therapeutic Agents for Incorporation into Nanocarriers: In Silico, In Vitro, Molecular Docking Evaluations. Pharmaceutics. 2025; 17(6):722.
https://doi.org/10.3390/pharmaceutics17060722
Chicago/Turabian Style
Peter, Sijongesonke, Eric Morifi, Mutshinyalo Nwamadi, Samson Olaitan Oselusi, Asongwe Lioniel Tantoh, Thierry Youmbi Fonkui, Derek Tantoh Ndinteh, and Blessing Atim Aderibigbe.
2025. "Ferrocene-Based Hybrid Drugs as Potential Anticancer and Antibacterial Therapeutic Agents for Incorporation into Nanocarriers: In Silico, In Vitro, Molecular Docking Evaluations" Pharmaceutics 17, no. 6: 722.
https://doi.org/10.3390/pharmaceutics17060722
APA Style
Peter, S., Morifi, E., Nwamadi, M., Oselusi, S. O., Tantoh, A. L., Fonkui, T. Y., Ndinteh, D. T., & Aderibigbe, B. A.
(2025). Ferrocene-Based Hybrid Drugs as Potential Anticancer and Antibacterial Therapeutic Agents for Incorporation into Nanocarriers: In Silico, In Vitro, Molecular Docking Evaluations. Pharmaceutics, 17(6), 722.
https://doi.org/10.3390/pharmaceutics17060722
